Estrogen receptors and their implications in colorectal carcinogenesis

Frontiers in Oncology

Volumn 5, Issue FEB, 2015, Pages

  Caiazza, Francesco ^a,b   Ryan, Elizabeth J ^a,b   Doherty, Glen ^a,b   Winter, Desmond C ^a   Sheahan, Kieran ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Colorectal cancer; Estrogen; Estrogen receptor; Tumor immunology; Tumor microenvironment

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR 3; ESTROGEN RECEPTOR 4; ESTROGEN RECEPTOR 5; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID HORMONE; TAMOXIFEN; UNCLASSIFIED DRUG;

CANCER GROWTH; CARCINOGENESIS; CELL FUNCTION; CELL PROLIFERATION; COLON MUCOSA; COLORECTAL CANCER; DISEASE COURSE; HORMONE SUBSTITUTION; HUMAN; IMMUNOSURVEILLANCE; INTRACELLULAR SIGNALING; LIFESTYLE; MICROSATELLITE INSTABILITY; NONHUMAN; OBESITY; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; TUMOR MICROENVIRONMENT;

EID: 84923224188     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00019     Document Type: Review

References (112)

1. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med (2002) 346:340-52. doi:10.1056/NEJMra000471
2. Burns KA, Korach KS. Estrogen receptors and human disease: an update. Arch Toxicol (2012) 86:1491-504. doi:10.1007/s00204-012-0868-5
3. Kennelly R, Kavanagh DO, Hogan AM, Winter DC. Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol (2008) 9:385-91. doi:10.1016/S1470-2045(08)70100-1
4. Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med (2006) 27:299-402. doi:10.1016/j.mam.2006.07.001
5. Marino M, Caiazza F. Estrogen signal transduction pathways from plasma membrane to the nucleus. In: Grachevsky NO, editor. Signal Transduction Research Trends. New York, NY: Nova Science Publisher (2007). p. 17-44.
6. O'Malley BW. A life-long search for the molecular pathways of steroid hormone action. Mol Endocrinol (2005) 19:1402-11. doi:10.1210/me.2004-0480
7. Hammes SR, Levin ER. Extranuclear steroid receptors: nature and actions. Endocr Rev (2007) 28:726-41. doi:10.1210/er.2007-0022
8. Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol (2005) 19:833-42. doi:10.1210/me.2004-0486
9. Levin ER. Extranuclear estrogen receptor's roles in physiology: lessons from mouse models. Am J Physiol Endocrinol Metab (2014) 307:E133-40. doi:10.1152/ajpendo.00626.2013
10. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, et al. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J (2001) 20:6050-9. doi:10.1093/emboj/20.21.6050
11. Acconcia F, Totta P, Ogawa S, Cardillo I, Inoue S, Leone S, et al. Survival versus apoptotic 17beta-estradiol effect: role of ER alpha and ER beta activated non-genomic signaling. J Cell Physiol (2005) 203:193-201. doi:10.1002/jcp.20219
12. Thomas C, Gustafsson JÅ. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer (2011) 11:597-608. doi:10.1038/nrc3093
13. Galluzzo P, Caiazza F, Moreno S, Marino M. Role of ERbeta palmitoylation in the inhibition of human colon cancer cell proliferation. Endocr Relat Cancer (2007) 14:153-67. doi:10.1677/ERC-06-0020
14. Hamilton KJ, Arao Y, Korach KS. Estrogen hormone physiology: reproductive findings from estrogen receptor mutant mice. Reprod Biol (2014) 14:3-8. doi:10.1016/j.repbio.2013.12.002
15. Saint-Criq V, Rapetti-Mauss R, Yusef YR, Harvey BJ. Estrogen regulation of epithelial ion transport: implications in health and disease. Steroids (2012) 77:918-23. doi:10.1016/j.steroids.2012.02.017
16. Rapetti-Mauss R, O'Mahony F, Sepulveda FV, Urbach V, Harvey BJ. Oestrogen promotes KCNQ1 potassium channel endocytosis and postendocytic trafficking in colonic epithelium. J Physiol (2013) 591:2813-31. doi:10.1113/jphysiol.2013.251678
17. O'Mahony F, Alzamora R, Chung H-L, Thomas W, Harvey BJ. Genomic priming of the antisecretory response to estrogen in rat distal colon throughout the estrous cycle. Mol Endocrinol (2009) 23:1885-99. doi:10.1210/me.2008-0248
18. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest (2006) 116:561-70. doi:10.1172/JCI27987
19. Jordan VC. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer (2007) 7:46-53. doi:10.1038/nrc2048
20. Syed V, Ulinski G, Mok SC, Yiu GK, Ho S-M. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res (2001) 61:6768-76.
21. Zannoni GF, Monterossi G, De Stefano I, Gargini A, Salerno MG, Farulla I, et al. The expression ratios of estrogen receptor a (ERa) to estrogen receptor ß1 (ERß1) and ERa to ERß2 identify poor clinical outcome in endometrioid endometrial cancer. Hum Pathol (2013) 44:1047-54. doi:10.1016/j.humpath.2012.09.007
22. Härkönen PL, Mäkelä SI. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol (2004) 92:297-305. doi:10.1016/j.jsbmb.2004.10.016
23. Siegfried JM. Smoking out reproductive hormone actions in lung cancer. Mol Cancer Res (2014) 12:24-31. doi:10.1158/1541-7786.MCR-13-0580
24. Hogan AM, Collins D, Baird AW, Winter DC. Estrogen and gastrointestinal malignancy. Mol Cell Endocrinol (2009) 307:19-24. doi:10.1016/j.mce.2009.03.016
25. Jordan VC, Brodie AMH. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids (2007) 72:7-25. doi:10.1016/j.steroids.2006.10.009
26. Stabile LP, Davis ALG, Gubish CT, Hopkins TM, Luketich JD, Christie N, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res (2002) 62:2141-50.
27. Olivo-Marston SE, Mechanic LE, Mollerup S, Bowman ED, Remaley AT, Forman MR, et al. Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women. Carcinogenesis (2010) 31:1778-86. doi:10.1093/carcin/bgq156
28. Risbridger GP, Davis ID, Birrell SN, Tilley WD. Breast and prostate cancer: more similar than different. Nat Rev Cancer (2010) 10:205-12. doi:10.1038/nrc2795
29. Dey P, Barros RPA, Warner M, Ström A, Gustafsson JÅ. Insight into the mechanisms of action of estrogen receptor ß in the breast, prostate, colon, and CNS. J Mol Endocrinol (2013) 51:T61-74. doi:10.1530/JME-13-0150
30. Hapangama DK, Kamal AM, Bulmer JN. Estrogen receptor ß: the guardian of the endometrium. Hum Reprod Update (2014). doi:10.1093/humupd/dmu053
31. Bossard C, Busson M, Vindrieux D, Gaudin F, Machelon V, Brigitte M, et al. Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer. PLoS One (2012) 7:e44787. doi:10.1371/journal.pone.0044787
32. Elbanna HG, Ebrahim MA, Abbas AM, Zalata K, Hashim MA. Potential value of estrogen receptor beta expression in colorectal carcinoma: interaction with apoptotic index. J Gastrointest Cancer (2012) 43:56-62. doi:10.1007/s12029-010-9214-4
33. Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer (2003) 39:1251-8. doi:10.1016/S0959-8049(03)00239-9
34. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res (2000) 60:245-8.
35. Rudolph A, Toth C, Hoffmeister M, Roth W, Herpel E, Jansen L, et al. Expression of oestrogen receptor ß and prognosis of colorectal cancer. Br J Cancer (2012) 107:831-9. doi:10.1038/bjc.2012.323
36. Jassam N, Bell SM, Speirs V, Quirke P. Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes' staging. Oncol Rep (2005) 14:17-21. doi:10.3892/or.14.1.17
37. Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, Ström A, et al. Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res (2009) 69:6100-6. doi:10.1158/0008-5472.CAN-09-0506
38. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin (2011) 61:69-90. doi:10.3322/caac.20107
39. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 136(5):E359-86. doi:10.1002/ijc.29210
40. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. globocaniarcfr. (2014). Available from: http://globocan.iarc.fr
41. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 350:991-1004. doi:10.1056/NEJMoa032071
42. Simon MS, Chlebowski RT, Wactawski-Wende J, Johnson KC, Muskovitz A, Kato I, et al. Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol (2012) 30:3983-90. doi:10.1200/JCO.2012.42.7732
43. Barzi A, Lenz AM, Labonte MJ, Lenz H-J. Molecular pathways: estrogen pathway in colorectal cancer. Clin Cancer Res (2013) 19:5842-8. doi:10.1158/1078-0432.CCR-13-0325
44. Rudolph A, Toth C, Hoffmeister M, Roth W, Herpel E, Schirmacher P, et al. Colorectal cancer risk associated with hormone use varies by expression of estrogen receptor-ß. Cancer Res (2013) 73:3306-15. doi:10.1158/0008-5472.CAN-12-4051
45. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2011) 60:397-411. doi:10.1136/gut.2010.217182
46. Lin JH, Morikawa T, Chan AT, Kuchiba A, Shima K, Nosho K, et al. Postmenopausal hormone therapy is associated with a reduced risk of colorectal cancer lacking CDKN1A expression. Cancer Res (2012) 72:3020-8. doi:10.1158/0008-5472.CAN-11-2619
47. Wu AH, Siegmund KD, Long TI, Cozen W, Wan P, Tseng C-C, et al. Hormone therapy, DNA methylation and colon cancer. Carcinogenesis (2010) 31:1060-7. doi:10.1093/carcin/bgq009
48. Limburg PJ, Limsui D, Vierkant RA, Tillmans LS, Wang AH, Lynch CF, et al. Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women. Cancer Epidemiol Biomarkers Prev (2012) 21:681-4. doi:10.1158/1055-9965.EPI-11-1168
49. Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, et al. Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. Gut (2012) 61:1299-305. doi:10.1136/gutjnl-2011-300719
50. Yan L, Spitznagel EL, Bosland MC. Soy consumption and colorectal cancer risk in humans: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2010) 19:148-58. doi:10.1158/1055-9965.EPI-09-0856
51. Guo J-Y, Li X, Browning JD, Rottinghaus GE, Lubahn DB, Constantinou A, et al. Dietary soy isoflavones and estrone protect ovariectomized ERalphaKO and wild-type mice from carcinogen-induced colon cancer. J Nutr (2004) 134:179-82.
52. Flood DM, Weiss NS, Cook LS, Emerson JC, Schwartz SM, Potter JD. Colorectal cancer incidence in Asian migrants to the United States and their descendants. Cancer Causes Control (2000) 11:403-11. doi:10.1023/A:1008955722425
53. Kim S-E, Shim K-N, Jung S-A, Yoo K, Moon IH. An association between obesity and the prevalence of colonic adenoma according to age and gender. J Gastroenterol (2007) 42:616-23. doi:10.1007/s00535-007-2074-4
54. Aleksandrova K, Drogan D, Boeing H, Jenab M, Bas Bueno-de-Mesquita H, Jansen E, et al. Adiposity, mediating biomarkers and risk of colon cancer in the European prospective investigation into cancer and nutrition study. Int J Cancer (2013) 134:612-21. doi:10.1002/ijc.28368
55. Yakar S, Nunez NP, Pennisi P, Brodt P, Sun H, Fallavollita L, et al. Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones. Endocrinology (2006) 147:5826-34. doi:10.1210/en.2006-0311
56. Sikalidis AK, Varamini B. Roles of hormones and signaling molecules in describing the relationship between obesity and colon cancer. Pathol Oncol Res (2011) 17:785-90. doi:10.1007/s12253-010-9352-9
57. Ho GYF, Wang T, Gunter MJ, Strickler HD, Cushman M, Kaplan RC, et al. Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res (2012) 72:3029-37. doi:10.1158/0008-5472.CAN-11-2771
58. Yi KW, Shin J-H, Seo HS, Lee JK, Oh M-J, Kim T, et al. Role of estrogen receptor-alpha and -beta in regulating leptin expression in 3T3-L1 adipocytes. Obesity (Silver Spring) (2008) 16:2393-9. doi:10.1038/oby.2008.389
59. McTiernan A. Mechanisms linking physical activity with cancer. Nat Rev Cancer (2008) 8:205-11. doi:10.1038/nrc2325
60. Xie L-Q, Yu J-P, Luo H-S. Expression of estrogen receptor beta in human colorectal cancer. World J Gastroenterol (2004) 10:214-7.
61. Passarelli MN, Phipps AI, Potter JD, Makar KW, Coghill AE, Wernli KJ, et al. Common single-nucleotide polymorphisms in the estrogen receptor ß promoter are associated with colorectal cancer survival in postmenopausal women. Cancer Res (2013) 73:767-75. doi:10.1158/0008-5472.CAN-12-2484
62. Grivas PD, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z, Papavassiliou AG, Kalofonos H. Estrogen receptor a/ß, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance? Int J Colorectal Dis (2009) 24:613-22. doi:10.1007/s00384-009-0647-9
63. Wada-Hiraike O, Imamov O, Hiraike H, Hultenby K, Schwend T, Omoto Y, et al. Role of estrogen receptor beta in colonic epithelium. Proc Natl Acad Sci USA (2006) 103:2959-64. doi:10.1073/pnas.0511271103
64. Saleiro D, Murillo G, Benya RV, Bissonnette M, Hart J, Mehta RG. Estrogen receptor-ß protects against colitis-associated neoplasia in mice. Int J Cancer (2012) 131:2553-61. doi:10.1002/ijc.27578
65. Giroux V, Lemay F, Bernatchez G, Robitaille Y, Carrier JC. Estrogen receptor beta deficiency enhances small intestinal tumorigenesis in ApcMin/+ mice. Int J Cancer (2008) 123:303-11. doi:10.1002/ijc.23532
66. Tu Z, Ma Y, Tian J, Li H, Akers W, Achilefu S, et al. Estrogen receptor ß potentiates the antiproliferative effect of raloxifene and affects the cell migration and invasion in HCT-116 colon cancer cells. J Cancer Res Clin Oncol (2012) 138:1091-103. doi:10.1007/s00432-011-1145-3
67. Janakiram NB, Mohammed A, Brewer M, Bryant T, Biddick L, Lightfoot S, et al. Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells. Cancer Prev Res (Phila) (2014) 7:300-9. doi:10.1158/1940-6207.CAPR-13-0345
68. Armstrong CM, Billimek AR, Allred KF, Sturino JM, Weeks BR, Allred CD. A novel shift in estrogen receptor expression occurs as estradiol suppresses inflammation-associated colon tumor formation. Endocr Relat Cancer (2013) 20:515-25. doi:10.1530/ERC-12-0308
69. Kramer F, Johnson IT, Doleman JF, Lund EK. A comparison of the effects of soya isoflavonoids and fish oil on cell proliferation, apoptosis and the expression of oestrogen receptors alpha and beta in the mammary gland and colon of the rat. Br J Nutr (2009) 102:29-36. doi:10.1017/S0007114508137862
70. Weyant MJ, Carothers AM, Mahmoud NN, Bradlow HL, Remotti H, Bilinski RT, et al. Reciprocal expression of ERalpha and ERbeta is associated with estrogen-mediated modulation of intestinal tumorigenesis. Cancer Res (2001) 61:2547-51.
71. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun (1998) 247:75-8. doi:10.1006/bbrc.1998.8738
72. Leung Y-K, Mak P, Hassan S, Ho S-M. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci USA (2006) 103:13162-7. doi:10.1073/pnas.0605676103
73. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Functional estrogen receptor beta in colon cancer cells. Biochem Biophys Res Commun (1999) 261:521-7. doi:10.1006/bbrc.1999.1062
74. Wong NACS, Malcomson RDG, Jodrell DI, Groome NP, Harrison DJ, Saunders PTK. ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J Pathol (2005) 207:53-60. doi:10.1002/path.1807
75. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H, et al. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum (2010) 53:57-64. doi:10.1007/DCR.0b013e3181c703a4
76. Sugai T, Habano W, Jiao Y-F, Tsukahara M, Takeda Y, Otsuka K, et al. Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas. J Mol Diagn (2006) 8:193-201. doi:10.2353/jmoldx.2006.050052
77. Nawa T, Kato J, Kawamoto H, Okada H, Yamamoto H, Kohno H, et al. Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol (2008) 23:418-23. doi:10.1111/j.1440-1746.2007.04923.x
78. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer (2002) 101:403-8. doi:10.1002/ijc.10635
79. Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol (2014) 25:1995-2001. doi:10.1093/annonc/mdu275
80. Koo JH, Leong RWL. Sex differences in epidemiological, clinical and pathological characteristics of colorectal cancer. J Gastroenterol Hepatol (2010) 25:33-42. doi:10.1111/j.1440-1746.2009.05992.x
81. Ward R, Meagher A, Tomlinson I, O'Connor T, Norrie M, Wu R, et al. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut (2001) 48:821-9. doi:10.1136/gut.48.6.821
82. Slattery ML, Potter JD, Curtin K, Edwards S, Ma KN, Anderson K, et al. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res (2001) 61:126-30.
83. He Y-Q, Sheng J-Q, Ling X-L, Fu L, Jin P, Yen L, et al. Estradiol regulates miR-135b and mismatch repair gene expressions via estrogen receptor-ß in colorectal cells. Exp Mol Med (2012) 44:723. doi:10.3858/emm.2012.44.12.079
84. Goldstone R, Itzkowitz S, Harpaz N, Ullman T. Progression of low-grade dysplasia in ulcerative colitis: effect of colonic location. Gastrointest Endosc (2011) 74:1087-93. doi:10.1016/j.gie.2011.06.028
85. Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, Giovannucci E, et al. Colorectal cancer: a tale of two sides or a continuum? Gut (2012) 61:794-7. doi:10.1136/gutjnl-2012-302014
86. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut (2012) 61:847-54. doi:10.1136/gutjnl-2011-300865
87. Rosty C, Young JP, Walsh MD, Clendenning M, Sanderson K, Walters RJ, et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One (2013) 8:e65479. doi:10.1371/journal.pone.0065479
88. Phipps AI, Chan AT, Ogino S. Anatomic subsite of primary colorectal cancer and subsequent risk and distribution of second cancers. Cancer (2013) 119:3140-7. doi:10.1002/cncr.28076
89. Parmeggiani D, Avenia N, Gubitosi A, Gilio F, Atelli PF, Agresti M. Additional prognostic factors in right colon cancer staging. Updates Surg (2011) 63:155-61. doi:10.1007/s13304-011-0078-3
90. Pollard KM. Gender differences in autoimmunity associated with exposure to environmental factors. J Autoimmun (2012) 38:J177-86. doi:10.1016/j.jaut.2011.11.007
91. Saleh M, Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol (2010) 11:9-20. doi:10.1038/nri2891
92. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 29:235-71. doi:10.1146/annurev-immunol-031210-101324
93. Edvardsson K, Ström A, Jonsson P, Gustafsson JÅ, Williams C. Estrogen receptor ß induces antiinflammatory and antitumorigenic networks in colon cancer cells. Mol Endocrinol (2011) 25:969-79. doi:10.1210/me.2010-0452
94. Zhu L, Cheng X, Ding Y, Shi J, Jin H, Wang H, et al. Bone marrow-derived myofibroblasts promote colon tumorigenesis through the IL-6/JAK2/STAT3 pathway. Cancer Lett (2014) 343:80-9. doi:10.1016/j.canlet.2013.09.017
95. Grivennikov S, Karin E, Terzic J, Mucida D, Yu G-Y, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 15:103-13. doi:10.1016/j.ccr.2009.01.001
96. Kovats S, Carreras E. Regulation of dendritic cell differentiation and function by estrogen receptor ligands. Cell Immunol (2008) 252:81-90. doi:10.1016/j.cellimm.2007.10.008
97. Carreras E, Turner S, Frank MB, Knowlton N, Osban J, Centola M, et al. Estrogen receptor signaling promotes dendritic cell differentiation by increasing expression of the transcription factor IRF4. Blood (2010) 115:238-46. doi:10.1182/blood-2009-08-236935
98. Bengtsson AK, Ryan EJ, Giordano D, Magaletti DM, Clark EA. 17beta-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. Blood (2004) 104:1404-10. doi:10.1182/blood-2003-10-3380
99. Cvoro A, Tatomer D, Tee M-K, Zogovic T, Harris HA, Leitman DC. Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol (2008) 180:630-6. doi:10.4049/jimmunol.180.1.630
100. Simard J, Gingras S. Crucial role of cytokines in sex steroid formation in normal and tumoral tissues. Mol Cell Endocrinol (2001) 171:25-40. doi:10.1016/S0303-7207(00)00387-7
101. Menon R, Watson SE, Thomas LN, Allred CD, Dabney A, Azcarate-Peril MA, et al. Diet complexity and estrogen receptor ß status affect the composition of the murine intestinal microbiota. Appl Environ Microbiol (2013) 79:5763. doi:10.1128/AEM.01182-13
102. Totta P, Acconcia F, Leone S, Cardillo I, Marino M. Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor alpha and beta signalling. IUBMB Life (2004) 56:491-9. doi:10.1080/15216540400010792
103. Bulzomi P, Galluzzo P, Bolli A, Leone S, Acconcia F, Marino M. The pro-apoptotic effect of quercetin in cancer cell lines requires ERß-dependent signals. J Cell Physiol (2012) 227:1891-8. doi:10.1002/jcp.22917
104. Bolli A, Bulzomi P, Galluzzo P, Acconcia F, Marino M. Bisphenol A impairs estradiol-induced protective effects against DLD-1 colon cancer cell growth. IUBMB Life (2010) 62:684-7. doi:10.1002/iub.370
105. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, et al. Endocrine-disrupting chemicals: an endocrine society scientific statement. Endocr Rev (2009) 30:293-342. doi:10.1210/er.2009-0002
106. Bolli A, Marino M. Current and future development of estrogen receptor ligands: applications in estrogen-related cancers. Recent Pat Endocr Metab Immune Drug Discov (2011) 5:210-29. doi:10.2174/187221411797265881
107. van Halteren H, Mulder D, Ruijter E. Oestrogen receptor-beta as a potential target for treatment in advanced colorectal cancer: a pilot study. Histopathology (2014) 64:787-90. doi:10.1111/his.12340
108. Caiazza F, Galluzzo P, Lorenzetti S, Marino M. 17Beta-estradiol induces ERbeta up-regulation via p38/MAPK activation in colon cancer cells. Biochem Biophys Res Commun (2007) 359:102-7. doi:10.1016/j.bbrc.2007.05.059
109. Al-Nakhle H, Smith L, Bell SM, Burns PA, Cummings M, Hanby AM, et al. Regulation of estrogen receptor ß1 expression in breast cancer by epigenetic modification of the 5' regulatory region. Int J Oncol (2013) 43:2039-45. doi:10.3892/ijo.2013.2112
110. Patel HK, Siklos MI, Abdelkarim H, Mendonca EL, Vaidya A, Petukhov PA, et al. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy. ChemMedChem (2014) 9:602-13. doi:10.1002/cmdc.201300270
111. Tu Z, Ma Y, Akers W, Achilefu S, Gu Y. Therapeutic effect of the treatment for colorectal cancer with adenoviral vectors mediated estrogen receptor ß gene therapy combined with thermotherapy. J Cancer Res Clin Oncol (2014) 140:623-32. doi:10.1007/s00432-014-1611-9
112. Wardell SE, Nelson ER, McDonnell DP. From empirical to mechanism-based discovery of clinically useful selective estrogen receptor modulators (SERMs). Steroids (2014) 90:30-8. doi:10.1016/j.steroids.2014.07.013